Viatris’ Once-Monthly Copaxone Filing Imminent, Botox ‘On Track’

Recent Approval For Revance Brand Encourages Viatris On Botox

 
• By Dean Rudge

Fresh from offloading almost all its interests in biosimilars to Biocon, Viatris continues to develop several follow-on products, which it hopes will add $1bn to the company’s top line by the end of the decade.

multiple sclerosis
Viatris is looking to expand its MS portfolio • Source: Alamy

Viatris remains confident of filing its proposed once monthly glatiramer acetate product, a follow-on to Teva’s Copaxone treatment for multiple sclerosis, in the US during Q1 following the recent conclusion of a pivotal Phase III clinical trial.

Subject to regulatory timelines, Viatris believes that it could launch the proposed 505(b)(2) glatiramer acetate product in 2024.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Value Added Medicines

More from Products